Abstract:Objective:To investigate the expression of fermitin family homolog 1 (FERMT1) protein in tissue samples of patients with gallbladder carcinoma and its relationship with clinical prognosis, and the pathologic impact of FERMT1 on proliferation and invasion of gallbladder cancer (GBC) cells.Methods:The clinical data of 30 patients with gallbladder cancer admitted in Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine from June 2016 to December 2018 were retrospectively analyzed. The patients were followed-up by outpatient examination and telephone interview until December 2020. The expression level of FERMT1 protein in tumor tissues and adjacent tissues of the 30 patients with gallbladder cancer was detected by immunohistochemistry and its relation with clinical characteristics and prognosis was analyzed. The FERMT1 gene in gallbladder cancer cells NOZ and GBC-SD was knocked down by small interference RNA. Gallbladder cancer cells were divided into FERMT1 knockdown group (si-FERMT1) and negative control group (si-NC). Cell proliferation activity was detected by cell counting kit-8 (CCK-8) assay. Cell invasion ability was evaluated by Transwell method. The expression levels of epithelial-mesenchymal transition (EMT) markers were detected by Western blotting. T-test was used between the two groups. Results:The positive rate of FERMT1 protein expression in gallbladder carcinoma (33.00%, 9/30) was higher than that in paracancerous tissues (3.33%, 1/30, P< 0.05). The expression of FERMT1 in tissue samples was closely related to TNM stage and lymph node metastasis ( P<0.05). The median survival of GBC patients expressing higher FERMT1 was 14 month compared to 18 months observed in patients expressing lower FERMT1 (Log-rank=3.875, P<0.05). The CCK-8 assay indicated that at 96 h after transfection, the absorbance values of si-FERMT1 group in NOZ cells was 0.773±0.046, which was significantly lower than in the si-NC group (1.124±0.043, t=12.395, P<0.01). The absorbance values of the si-FERMT1 group in GBC-SD cells was 0.538±0.022, which was significantly lower than in the si-NC group (0.778±0.03, t=13.457, P<0.01). Transwell experiments showed that the number of invasive cells in the si-FERMT1 group in NOZ cells was (178.00±15.72), which was less than in si-NC group (430.33±20.60, t=16.874, P<0.01). The number of invasive cells in the si-FERMT1 group in GBC-SD cells was (130.33±11.72), which was less than in si-NC group (414.67±20.53, t=20.842, P<0.01). Conclusion:FERMT1 is highly expressed in GBC and is related to the development and poor prognosis of GBC. FERMT1 plays a tumor-promoting role in the formation and development of GBC.

FERMT1 suppression induces anti-tumor effects and reduces stemness in glioma cancer cells

The Role of FERMT2 in the Tumor Microenvironment and Immunotherapy in Pan-Cancer Using Comprehensive Single-Cell and Bulk Sequencing

FERMT1 knockdown inhibits oral squamous cell carcinoma cell epithelial-mesenchymal transition by inactivating the PI3K/AKT signaling pathway

FERMT1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma by activating EGFR/AKT/β-catenin and EGFR/ERK pathways

FERMT1 contributes to the progression of prostate cancer through the p53 pathway

Expression level and pathologic function of fermitin family homolog 1 in gallbladder cancer development

FER1L4/miR-372/E2F1 works as a ceRNA system to regulate the proliferation and cell cycle of glioma cells.

FERMT1 promotes gastric cancer progression by activating the NF-B pathway and predicts poor prognosis

Ferroptosis Activation Scoring Model Assists in Chemotherapeutic Agents’ Selection and Mediates Cross-Talk with Immunocytes in Malignant Glioblastoma

Intracellular C5aR1 inhibits ferroptosis in glioblastoma through METTL3-dependent m6A methylation of GPX4

Modulation of Tumor Immune Microenvironment and Prognostic Value of Ferroptosis-Related Genes, and Candidate Target Drugs in Glioblastoma Multiforme

Ferritin light chain promotes the reprogramming of glioma immune microenvironment and facilitates glioma progression

MicroRNA-670-3p Suppresses Ferroptosis of Human Glioblastoma Cells Through Targeting ACSL4

Overexpression of carnitine palmitoyltransferase 1A promotes mitochondrial fusion and differentiation of glioblastoma stem cells

Hypoxia Induced Ferritin Light Chain (FTL) Promoted Epithelia Mesenchymal Transition and Chemoresistance of Glioma

Transcriptional Patterns of Lower-Grade Glioma Patients with Distinct Ferroptosis Levels, Immunotherapy Response, and Temozolomide Sensitivity

Adaptive Changes Allow Targeting of Ferroptosis for Glioma Treatment

FHOD1 is Upregulated in Glioma Cells and Attenuates Ferroptosis of Glioma Cells by Targeting HSPB1 Signaling

SLC1A5 enhances malignant phenotypes through modulating ferroptosis status and immune microenvironment in glioma

PRMT1 promotes radiotherapy resistance in glioma stem cells by inhibiting ferroptosis

O-GlcNAcylation of ZEB1 Facilitated Mesenchymal Pancreatic Cancer Cell Ferroptosis